MCID: DYS011
MIFTS: 32

Dyskinesia of Esophagus

Categories: Gastrointestinal diseases

Aliases & Classifications for Dyskinesia of Esophagus

MalaCards integrated aliases for Dyskinesia of Esophagus:

Name: Dyskinesia of Esophagus 12 14
Esophageal Motility Disorders 52 42 69
Esophageal Motility Disorder 12
Oesophageal Motor Disorder 12
Dyskinesia of Oesophagus 12
Oesophageal Dysmotility 12
Esophageal Dysmotility 12
Esophageal Spasm 69

Classifications:



External Ids:

Disease Ontology 12 DOID:9192
ICD10 33 K22.4
ICD9CM 35 530.5
MeSH 42 D015154
UMLS 69 C0014858

Summaries for Dyskinesia of Esophagus

MalaCards based summary : Dyskinesia of Esophagus, also known as esophageal motility disorders, is related to crest syndrome and cloacal exstrophy, and has symptoms including spasm An important gene associated with Dyskinesia of Esophagus is TEF (TEF, PAR BZIP Transcription Factor). The drugs Domperidone and Dopamine have been mentioned in the context of this disorder. Affiliated tissues include testes, lung and bone.

Related Diseases for Dyskinesia of Esophagus

Diseases related to Dyskinesia of Esophagus via text searches within MalaCards or GeneCards Suite gene sharing:

(show all 40)
id Related Disease Score Top Affiliating Genes
1 crest syndrome 11.4
2 cloacal exstrophy 10.4 ATP4A TEF
3 paracoccidioidomycosis 10.4 ATP4A TEF
4 cryptogenic organizing pneumonia 10.4 ATP4A TEF
5 esophagitis 10.4
6 frontal sinus schneiderian papilloma 10.3 ATP4A TEF
7 mesenteric vascular occlusion 10.2 ATP4A TOP1
8 parotid disease 10.1 CENPB TOP1
9 cardiomyopathy, hypertrophic, 7 10.0 RP9 UBTF
10 physical urticaria 10.0 CENPB TOP1
11 calcinosis 9.9
12 autonomic neuropathy 9.9
13 neuropathy 9.9
14 chronic fatigue syndrome 9.9 CENPB TOP1
15 bronchiectasis 9.9
16 tracheoesophageal fistula 9.9
17 enamel erosion 9.8 ATP4A TOP1 UBTF
18 tuberculum sellae meningioma 9.8 ATP4A TEF
19 respiratory system disease 9.8 CENPB TOP1
20 vaginal spindle cell epithelioma 9.8 CENPB TOP1
21 velocardiofacial syndrome 9.7
22 actinomycosis 9.7
23 temporomandibular ankylosis 9.7 CENPB TOP1
24 schizophrenia 9.7
25 asthma 9.7
26 gillespie syndrome 9.7
27 gastroesophageal reflux 9.7
28 palatopharyngeal incompetence 9.7
29 pulmonary hypertension 9.7
30 pulmonary fibrosis 9.7
31 esophageal atresia 9.7
32 myxedema 9.7
33 gastroparesis 9.7
34 paranoid schizophrenia 9.7
35 telangiectasis 9.7
36 myositis 9.7
37 intrinsic asthma 9.7
38 cutaneous sclerosis 9.7
39 diffuse scleroderma 9.7 CENPB TOP1 UBTF
40 periodic limb movement disorder 7.1 AGBL3 ATP4A CENPB DEGS2 RP9 TEF

Comorbidity relations with Dyskinesia of Esophagus via Phenotypic Disease Network (PDN): (show all 20)


Acute Cystitis Anxiety Disorder
Bronchitis Chronic Myocardial Ischemia
Deficiency Anemia Dysthymic Disorder
Esophageal Disease Esophagitis
Gastroesophageal Reflux Heart Disease
Hypertension, Essential Hypothyroidism
Intermediate Coronary Syndrome Irritable Bowel Syndrome
Ischemic Heart Disease Megaesophagus
Mitral Valve Disease Osteoporosis
Protein-Energy Malnutrition Swallowing Disorders

Graphical network of the top 20 diseases related to Dyskinesia of Esophagus:



Diseases related to Dyskinesia of Esophagus

Symptoms & Phenotypes for Dyskinesia of Esophagus

UMLS symptoms related to Dyskinesia of Esophagus:


spasm

Drugs & Therapeutics for Dyskinesia of Esophagus

Drugs for Dyskinesia of Esophagus (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 248)
id Name Status Phase Clinical Trials Cas Number PubChem Id
1
Domperidone Approved, Investigational, Vet_approved Phase 4,Phase 3 57808-66-9 3151
2
Dopamine Approved Phase 4,Phase 3 51-61-6, 62-31-7 681
3
Omeprazole Approved, Investigational, Vet_approved Phase 4,Phase 3,Phase 2,Phase 1 73590-58-6 4594
4
Alginic acid Approved, Experimental Phase 4,Phase 3,Phase 1 9005-32-7
5
Esomeprazole Approved, Investigational Phase 4,Phase 2,Phase 3,Phase 1 161796-78-7, 119141-88-7 4594 9579578
6
Dexlansoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 138530-94-6, 103577-45-3 9578005
7
Lansoprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1 103577-45-3 3883
8
Rabeprazole Approved, Investigational Phase 4,Phase 3,Phase 2,Phase 1 117976-89-3 5029
9
Pantoprazole Approved Phase 4,Phase 3,Phase 2,Phase 1 102625-70-7 4679
10
Menthol Approved Phase 4,Phase 1,Phase 2 2216-51-5 16666
11
Dronabinol Approved, Illicit Phase 4 1972-08-3 16078 2978
12
Magnesium Hydroxide Approved Phase 4,Phase 1 1309-42-8
13
Aluminum hydroxide Approved Phase 4,Phase 3,Phase 1 21645-51-2
14 Magnesium trisilicate Approved Phase 4,Phase 3,Phase 1 14987-04-3
15
Nortriptyline Approved Phase 4,Phase 2,Phase 3 72-69-5 4543
16
Pectin Approved, Vet_approved Phase 4 9000-69-5 441476
17
Ethanol Approved Phase 4 64-17-5 702
18
Cimetidine Approved Phase 4 51481-61-9 2756
19
Famotidine Approved Phase 4,Phase 2,Phase 3 76824-35-6 3325
20
Histamine Approved, Investigational Phase 4,Phase 3,Phase 2 75614-87-8, 51-45-6 774
21
Metoclopramide Approved, Investigational Phase 4,Phase 3 364-62-5 4168
22
Nizatidine Approved Phase 4,Phase 3 76963-41-2 3033637
23
Ranitidine Approved Phase 4,Phase 3,Phase 2 66357-59-3, 66357-35-5 3001055
24
Trimebutine Approved Phase 4 39133-31-8
25
Prednisone Approved, Vet_approved Phase 4 53-03-2 5865
26
Aripiprazole Approved, Investigational Phase 4 129722-12-9 60795
27
Asenapine Approved Phase 4 85650-56-2, 65576-45-6 3001386
28
Clozapine Approved Phase 4 5786-21-0 2818
29
Olanzapine Approved, Investigational Phase 4 132539-06-1 4585
30
Risperidone Approved, Investigational Phase 4 106266-06-2 5073
31
Valproic Acid Approved, Investigational Phase 4 99-66-1 3121
32
Ziprasidone Approved Phase 4 146939-27-7 60854
33
Amoxicillin Approved, Vet_approved Phase 4 26787-78-0 33613 2171
34
Clarithromycin Approved Phase 4 81103-11-9 84029
35
Citalopram Approved Phase 4 59729-33-8 2771
36
Methylene blue Investigational Phase 4 61-73-4
37 Mosapride Investigational Phase 4 112885-41-3
38 Rebamipide Investigational Phase 4 90098-04-7
39 Lafutidine Investigational Phase 4,Phase 3 118288-08-7
40
Maleic acid Experimental Phase 4 110-16-7 444266
41 Antacids Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
42 Antiemetics Phase 4,Phase 3
43 Anti-Ulcer Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
44 Autonomic Agents Phase 4,Phase 3,Phase 2,Phase 1
45 Dopamine Agents Phase 4,Phase 3
46 Dopamine Antagonists Phase 4,Phase 3
47 Gastrointestinal Agents Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1
48 Neurotransmitter Agents Phase 4,Phase 3,Phase 2,Phase 1
49 Peripheral Nervous System Agents Phase 4,Phase 3,Phase 2,Phase 1
50
Proton pump inhibitors Phase 4,Phase 3,Phase 2,Phase 1,Early Phase 1

Interventional clinical trials:

(show top 50) (show all 722)

id Name Status NCT ID Phase Drugs
1 Personalized Peroral Endoscopic Myotomy for Achalasia Unknown status NCT01570621 Phase 4
2 Research of Efficient Use of Omeprazole in Combination With Domperidone in Gastroesophageal Reflux Disease of Mild to Moderate Severity Unknown status NCT02140073 Phase 4 omeprazole+domperidone SR;omeprazole
3 Randomized, Double Blind, Placebo Control Trial to Evaluate the Efficacy of Wu-Chu-Yu Tang on Gastroesophageal Reflux Disease (GERD) Unknown status NCT01822106 Phase 4
4 Development of Applications of the Bravo® pH Monitoring System and Evaluation of Its Performance Unknown status NCT01503476 Phase 4
5 LGG for Prevention of Infectious Complications During PPI Treatment in Children Unknown status NCT01782118 Phase 4
6 Esomeprazole Plus Alginate vs. Esomeprazole Alone for Treatment of Nighttime Reflux Symptom and Sleep Disturbances Unknown status NCT02277886 Phase 4 sodium alginate;esomeprazole
7 Dexlansoprazole to Treat Laryngopharyngeal Reflux and Lingual Tonsil Hypertrophy Unknown status NCT01328652 Phase 4 dexlansoprazole
8 The Relationship Between Gastroesophageal Reflux and Pediatric Rhinitis: Significance of Pale/Blue Colored Turbinate Unknown status NCT02278081 Phase 4 lansoprazole;placebo
9 A Randomized, Double-Blind, Placebo-Controlled Study of Gastroesophageal Reflux Disease Therapy. Unknown status NCT00237068 Phase 4 Lansoprazole; Solutab
10 The Effect of Corticotrophin-releasing Hormone (CRH) on Esophageal Motility in Healthy Volunteers Completed NCT02736734 Phase 4 CRH
11 The Effects of Cannabinoid on Patients With Non-GERD Related Non Cardiac Chest Pain Completed NCT01598207 Phase 4 Marinol;Placebo
12 Comparing Clinical Efficacy of One-Week Dual Delayed-Release Dexlansoprazole and Esomeprazole for GERD Grade A and B Completed NCT03128736 Phase 4 Esomeprazole group;Dexlansoprazole group
13 The Efficacy of Lansoprazole and Domperidone Combination on Intragastric and Intraesophageal Acidity Completed NCT02958046 Phase 4 Lansoprazole/Domperidone
14 The Effect of Dexrabeprazole on Intragastric and Intraesophageal Acidity Completed NCT02689999 Phase 4 Dexrabeprazole 10 mg Enteric-Coated Tablets
15 Role of Pepsin Assay in Wheezy Infants Completed NCT02685436 Phase 4 Omeprazole and domperidone
16 Dexlansoprazole in Asian Participants With Gastroesophageal Reflux Disease Completed NCT02351960 Phase 4 Dexlansoprazole
17 Observational Study (This Means That no Drug is Tested) in Patients Suffering of Gastroesophageal Reflux Disease. Completed NCT01601379 Phase 4
18 Safety and Efficacy of Lansoprazole in Patients With Reflux Disease Completed NCT01135368 Phase 4 Lansoprazole
19 Practice and Patient Compliance on the PPI (Proton Pump Inhibitors) Treatment of Gastroesophageal Reflux in South Korea Completed NCT01018160 Phase 4 Rabeprazole Sodium
20 A Study of Nexium (Esomeprazole) 40 mg Once Daily in Subjects With Symptoms of Gastroesophageal Reflux Disease (GORD) After Treatment With a Full Dose of Proton Pump Inhibitor (PPI) Completed NCT00734097 Phase 4 Esomeprazole 40 mg
21 Role of Mosapride in Patients With Gastroesophageal Reflux Disease Completed NCT00729339 Phase 4 mosapride for the first month and placebo for the 2nd month;placebo for the first and mosapride for the second month
22 Local Phase IV, Gastroesophageal Reflux Disease (GERD) Sleep Study US Completed NCT00660660 Phase 4 Esomeprazole;Placebo
23 Open, Randomized, Two Way Crossover 40mg, Orally and Intravenously Completed NCT00635414 Phase 4 Esomeprazole;Esomeprazole
24 An Open, Randomized, Two Way Crossover Study Comparing the Effect of 20mg Esomeprazole Administered Orally and Intravenously as a 15 Minute Infusion on Basal and Pentagastrin-Stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Dise Completed NCT00629564 Phase 4 Esomeprazole;Esomeprazole
25 Open, Randomized, Two Way Crossover Study Comparing the Effect of Esomeprazole Adminstered Orally and iv Completed NCT00626262 Phase 4 Esomeprazole
26 Study Comparing the Effects of Esomeprazole Adminstered Orally and Intravenously on Basal and Pentrigastrin-stimulated Acid Output in Subjects With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00625495 Phase 4 Esomeprazole;Esomeprazole
27 Study to Assess Management Strategies for the Use of Esomeprazole (Nexium) in Helicobacter Pylori Infected Patients Completed NCT00574925 Phase 4 Esomeprazole
28 A Study to Compare the Number of Patients With Gastro-Oesophageal Reflux Disease (GORD) Achieving Heartburn and Regurgitation Symptom Resolution After Treatment With Either Rabeprazole Sodium 20mg, Esomeprazole 20mg or Esomeprazole 40mg Completed NCT00464308 Phase 4 Esomeprazole;Rabeprazole;Esomeprazole
29 Evaluation of 24-Hour Intragastric pH Using Esomeprazole, Lansoprazole, and Pantoprazole in Hispanic Patients With GERD Completed NCT00410592 Phase 4 Esomeprazole 40mg;Pantoprazole 40mg;Lansoprazole 30mg
30 Examine National Characteristics & Outcome Measures of GERD Patients Using the PPI Acid Suppression Symptom (PASS) Test for Response Completed NCT00392002 Phase 4 Esomeprazole
31 PPI Sequencing Study Completed NCT00384592 Phase 4 Esomeprazole
32 CYP2C19 Genetic Polymorphism on the Accuracy of Proton-Pump Inhibitor Testing Completed NCT00354757 Phase 4 rabeprazole
33 Symptom Adapted Therapy in GERD Patients Completed NCT00343161 Phase 4 esomeprazole;Gelusil-Lac (Aluminum hydroxide gel,magnesium trisilicate)
34 Comparison of the Classical Healing Concept With the Complete Remission Concept After Treatment With Pantoprazole in Adult Patients With Erosive GERD (Gastroesophageal Reflux Disease) (BY1023/M3-342) Completed NCT00325676 Phase 4 Pantoprazole
35 Comparison of the Nighttime Effects of Two Different Drugs on Subjects With GERD Completed NCT00304421 Phase 4 rabeprazole;pantoprazole
36 Validation of RDQ Questionnaire Completed NCT00291746 Phase 4 Esomeprazole
37 Esomeprazole in PPI Failures - IMPROVE Completed NCT00272701 Phase 4 Esomeprazole;Other PPI marketed in Sweden
38 Determination of a Questionnaire After Treatment With Pantoprazole at Full Dose and Half Dose in Adult Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/UK-506) Completed NCT00261339 Phase 4 Pantoprazole
39 Role of Pain Modulation in GERD Patients Who Failed Standard Dose Proton Pump Inhibitors (PPI) Completed NCT00251732 Phase 4 Standard dose (once daily) PPI plus low-dose antidepressant;Double dose PPI plus evening placebo;Rabeprazole , placebo, placebo
40 Determination of the Minimal Clinically Important Difference After Treatment With Pantoprazole in Patients With Symptoms of Acid Reflux (Gastroesophageal Reflux Disease) (BY1023/M3-340) Completed NCT00246909 Phase 4 Pantoprazole
41 An Open-Label Study of Once-Daily Oral Administration of Esomeprazole 40 mg in Patients With Symptoms of Gastroesophageal Reflux Disease (GERD) Completed NCT00242736 Phase 4 Esomeprazole
42 On Demand Treatment of Reflux Disease Completed NCT00184522 Phase 4 Aflurax;esomeprazole
43 Esomeprazole for Treatment of GERD in Pediatric Patients Completed NCT00228527 Phase 4 Esomeprazole (Nexium)
44 Omeprazole 20 mg in Patients With Laryngopharyngeal reflux and Comorbid Chronic Rhinosinusitis Completed NCT03086070 Phase 4 Omeprazole 20mg;Placebo oral capsule
45 A Study to Evaluate REbamiPide as an Adjuvant Regimen to Heal erosIve Reflux Esophagitis Completed NCT02755753 Phase 4 Lansoprazole;Rebamipide;Rebamipide-placebo
46 To Assess the Efficacy of Esomeprazole 20mg Once Daily in Subjects Who Still Had Heartburn After Receiving Rabeprazole Completed NCT01397084 Phase 4 esomeprazole 20 mg
47 An Efficacy Study to Compare the Treatment Effects of Rabeprazole and Lansoprazole Depending on the Genotyping of CYP2C19 in Treating Reflux Esophagitis Completed NCT01008696 Phase 4 Rabeprazole;Lansoprazole
48 The Role of Anti-Reflux Surgery for Gastroesophageal Reflux Disease in Premature Infants With Bronchopulmonary Dysplasia Completed NCT00926276 Phase 4
49 Nissen and Gastroplasty in Gastroesophageal Reflux Disease (GERD) Completed NCT00872755 Phase 4
50 Quality of Life Validation in Laryngitis Completed NCT00641264 Phase 4 Omeprazole

Search NIH Clinical Center for Dyskinesia of Esophagus

Inferred drug relations via UMLS 69 / NDF-RT 48 :


Cochrane evidence based reviews: esophageal motility disorders

Genetic Tests for Dyskinesia of Esophagus

Anatomical Context for Dyskinesia of Esophagus

MalaCards organs/tissues related to Dyskinesia of Esophagus:

39
Testes, Lung, Bone, Tongue, Tonsil, Thyroid, Adipocyte

Publications for Dyskinesia of Esophagus

Variations for Dyskinesia of Esophagus

Expression for Dyskinesia of Esophagus

Search GEO for disease gene expression data for Dyskinesia of Esophagus.

Pathways for Dyskinesia of Esophagus

GO Terms for Dyskinesia of Esophagus

Cellular components related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 fibrillar center GO:0001650 8.62 TOP1 UBTF

Biological processes related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 rhythmic process GO:0048511 8.62 TEF TOP1

Molecular functions related to Dyskinesia of Esophagus according to GeneCards Suite gene sharing:

id Name GO ID Score Top Affiliating Genes
1 double-stranded DNA binding GO:0003690 8.96 TEF TOP1
2 chromatin binding GO:0003682 8.8 CENPB TOP1 UBTF

Sources for Dyskinesia of Esophagus

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
16 ExPASy
18 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 MedGen
42 MeSH
43 MESH via Orphanet
44 MGI
46 NCI
47 NCIt
48 NDF-RT
51 NINDS
52 Novoseek
54 OMIM
55 OMIM via Orphanet
59 PubMed
60 QIAGEN
65 SNOMED-CT via HPO
66 SNOMED-CT via Orphanet
67 TGDB
68 Tocris
69 UMLS
70 UMLS via Orphanet
Content
Loading form....